These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24133744)

  • 1. Stent thrombosis following drug-eluting stents: conflict of generations.
    Nammas W
    J Invasive Cardiol; 2013 Sep; 25(9):A28. PubMed ID: 24133744
    [No Abstract]   [Full Text] [Related]  

  • 2. Stent thrombosis through the generations.
    Rajan L; Moliterno DJ
    J Invasive Cardiol; 2013 Jul; 25(7):337-8. PubMed ID: 23813061
    [No Abstract]   [Full Text] [Related]  

  • 3. Author reply: To PMID 23813060.
    Dores H; Raposo L
    J Invasive Cardiol; 2013 Sep; 25(9):A28-9. PubMed ID: 24133745
    [No Abstract]   [Full Text] [Related]  

  • 4. Stent thrombosis with second- versus first-generation drug-eluting stents in real-world percutaneous coronary intervention: analysis of 3806 consecutive procedures from a large-volume single-center prospective registry.
    Dores H; Raposo L; Campante Teles R; Machado C; Leal S; Araújo Gonçalves P; Mesquita Gabriel H; Sousa Almeida M; Mendes M
    J Invasive Cardiol; 2013 Jul; 25(7):330-6. PubMed ID: 23813060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
    Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary stent thrombosis in patients with chronic kidney disease: balancing anti-ischemic efficacy and hemorrhagic risk.
    Belardi JA; Albertal M
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):368-9. PubMed ID: 22933347
    [No Abstract]   [Full Text] [Related]  

  • 7. Late stent thrombosis: can it be prevented?
    Mauri L; Galper BZ
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1103-4. PubMed ID: 25341706
    [No Abstract]   [Full Text] [Related]  

  • 8. Recurrent very late drug-eluting stent thrombosis.
    Duchini M; Fournier S; Iglesias JF; Roguelov C; Muller O; Eeckhout E
    Int J Cardiol; 2013 Oct; 168(4):e111-2. PubMed ID: 23988303
    [No Abstract]   [Full Text] [Related]  

  • 9. Three years since the FDA advisory panel on drug-eluting stents: what have we learned about off-label use and stent thrombosis?
    Naidu SS
    J Invasive Cardiol; 2010 Jan; 22(1):20-1. PubMed ID: 20048394
    [No Abstract]   [Full Text] [Related]  

  • 10. Non-cardiac procedures after DES: an everyday issue awaiting answers.
    Esteves V; Lemos PA
    Catheter Cardiovasc Interv; 2015 Aug; 86(2):220. PubMed ID: 26198062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of everolimus-eluting stent implantation in patients with small coronary arteries (≤2.5 mm): outcomes of 3-year clinical follow-up.
    Yano H; Horinaka S; Ishikawa M; Ishimitsu T
    Heart Vessels; 2017 Jul; 32(7):796-803. PubMed ID: 28025695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The complexity of stenting in bifurcation coronary lesions.
    Kornowski R
    JACC Cardiovasc Interv; 2013 Jul; 6(7):696-7. PubMed ID: 23866181
    [No Abstract]   [Full Text] [Related]  

  • 13. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
    Maeng M; Tilsted HH; Jensen LO; Krusell LR; Kaltoft A; Kelbæk H; Villadsen AB; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Thuesen L; Madsen M; Thayssen P; Sørensen HT; Lassen JF
    Lancet; 2014 Jun; 383(9934):2047-2056. PubMed ID: 24631162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stent thrombosis following 2 drug-eluting stent implantations for coronary bifurcation lesion: a single-center analysis.
    Gao Z; Xu B; Yang Y; Chen J; Qiao S; Li JJ; Qin X; Wu Y; Yao M; Yuan J; Chen J; Liu H; Dai J; Gao RL
    J Interv Cardiol; 2010 Aug; 23(4):346-51. PubMed ID: 20718906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Very late stent thrombosis in everolimus-eluting stent with predisposing mechanical factors: Differential features.
    Jaguszewski MJ; Cortes C; Daucher H; Schincariol M; Halejcio M; Besuch P; Gutiérrez-Chico JL
    Cardiol J; 2017; 24(4):345-349. PubMed ID: 28831778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).
    Waksman R; Kirtane AJ; Torguson R; Cohen DJ; Ryan T; Räber L; Applegate R; Waxman S; Gordon P; Kaneshige K; Leon MB;
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1093-102. PubMed ID: 25240540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Vascular Imaging in Guiding Routine Percutaneous Coronary Interventions: A Meta-Analysis of Bare Metal Stent and Drug-Eluting Stent Trials.
    Alsidawi S; Effat M; Rahman S; Abdallah M; Leesar M
    Cardiovasc Ther; 2015 Dec; 33(6):360-6. PubMed ID: 26363283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial.
    Christiansen EH; Jensen LO; Thayssen P; Tilsted HH; Krusell LR; Hansen KN; Kaltoft A; Maeng M; Kristensen SD; Bøtker HE; Terkelsen CJ; Villadsen AB; Ravkilde J; Aarøe J; Madsen M; Thuesen L; Lassen JF;
    Lancet; 2013 Feb; 381(9867):661-9. PubMed ID: 23374649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.